RxDoctor Payments Data

Muhammad Siddiqui, MD

Hospice and Palliative Medicine · Manassas, VANPI 1093953168

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $560 and has fallen 83.5% since, to $92 in 2025.

$948in general payments, 2019–2025

Across 38 payments — averaging $24.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$130
  • Regeneron Healthcare Solutions, Inc.$120
  • AstraZeneca$80
  • Johnson & Johnson$78
  • Stemline Therapeutics Inc.$76
  • Daiichi Sankyo Inc.$72
  • plus $393 from 13 others

What the payments were for

  • Food & beverage$948100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$948 in reported general payments places this provider in the 85th percentile of 45 hospice and palliative medicine providers in Virginia.

See all hospice and palliative medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$59,508
Medicare patients
220
Services billed
444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl20$13,279
JanuviaSitagliptin Phosphate18$7,813
Xtampza ErOxycodone Myristate12$6,223
Pregabalin91$5,189
Fentanyl51$4,751
Hydromorphone ErHydromorphone Hcl18$4,251
Oxycodone Hcl280$4,057
Gabapentin216$3,516
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen154$3,452
Morphine Sulfate ErMorphine Sulfate110$2,668
Duloxetine Hcl52$1,296
Tramadol Hcl90$1,071
Mirtazapine41$1,042
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$871
Hydromorphone Hcl70$828

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$22$7,81318 claims
Lilly USA, LLCOlanzapine$24$30029 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 45 hospice and palliative medicine providers in Virginia.

Other hospice and palliative medicine in Manassas

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →